MA51073A - Inhibition de l'idh-1 mutante - Google Patents

Inhibition de l'idh-1 mutante

Info

Publication number
MA51073A
MA51073A MA051073A MA51073A MA51073A MA 51073 A MA51073 A MA 51073A MA 051073 A MA051073 A MA 051073A MA 51073 A MA51073 A MA 51073A MA 51073 A MA51073 A MA 51073A
Authority
MA
Morocco
Prior art keywords
inhibition
hdi
mutant
mutant hdi
Prior art date
Application number
MA051073A
Other languages
English (en)
Other versions
MA51073B1 (fr
Inventor
Susan Ashwell
Alan Collis
Jeff Davis
Patrick F Kelly
Blythe Thomson
Duncan Walker
Original Assignee
Forma Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Forma Therapeutics Inc filed Critical Forma Therapeutics Inc
Priority claimed from PCT/US2019/032747 external-priority patent/WO2019222553A1/fr
Publication of MA51073A publication Critical patent/MA51073A/fr
Publication of MA51073B1 publication Critical patent/MA51073B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA51073A 2018-05-16 2019-05-16 Inhibition de l'idh-1 mutante MA51073B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862672461P 2018-05-16 2018-05-16
PCT/US2019/032747 WO2019222553A1 (fr) 2018-05-16 2019-05-16 Inhibition de l'idh-1 mutante

Publications (2)

Publication Number Publication Date
MA51073A true MA51073A (fr) 2020-10-14
MA51073B1 MA51073B1 (fr) 2023-04-28

Family

ID=86227080

Family Applications (1)

Application Number Title Priority Date Filing Date
MA51073A MA51073B1 (fr) 2018-05-16 2019-05-16 Inhibition de l'idh-1 mutante

Country Status (1)

Country Link
MA (1) MA51073B1 (fr)

Also Published As

Publication number Publication date
MA51073B1 (fr) 2023-04-28

Similar Documents

Publication Publication Date Title
EP3833739A4 (fr) Souche d'akkermansia muciniphila
DK4045039T3 (da) Hæmning af human integrin-alfa4beta7
EP3526328A4 (fr) Polythérapie pour l'inhibition de c3
EP3692028A4 (fr) Inhibition de la peptidase 30 spécifique de l'ubiquitine
IL271046A (en) Compounds for treating huntington's disease
EP3906029A4 (fr) Inhibiteurs de l'interaction ménine-mll
EP3860449A4 (fr) Agencement d'électrodes
EP3768854A4 (fr) Modulation de l'expression de hsd17b13
MA52004A (fr) Inhibiteurs d'o-glycoprotéine-2-acétamido-2-désoxy-3-d-glycopyranosidase
EP3870179A4 (fr) Inhibition d'usp7
EP3449001A4 (fr) Inhibition de l'arnmi mir-22 par apt-110
EP3415146A4 (fr) Inhibiteur de l'activation des inflammasomes
EP3661552A4 (fr) Compositions et méthodes d'inhibition de l'élimination de mica/b
MA51337A (fr) Inhibiteurs spiro exo-aza de l'interaction ménine-mll
MA54521A (fr) Dérivés d'oxopyridine substitués
EP3402521A4 (fr) Inhibition de réaction allergique à l'aide d'un inhibiteur d'il-33
MA53648A (fr) Inhibiteurs d'o-glycoprotéine-2-acétamido-2-désoxy-3-d-glucopyranosidase
IL288230A (en) Identification of recurrent mutated neopeptides
EP3424868A4 (fr) Mécanisme d'extension/contraction
EP3746058A4 (fr) Compositions et méthodes d'amélioration de la biodisponibilité de 5-hydroxytryptophane
EP3768301A4 (fr) Compositions et méthodes d'inhibition de fas
EP3897902A4 (fr) Séparation d'oligosaccharides
MA43764A (fr) Inhibiteur monovalent de l'interaction hutnfr1
EP3965749A4 (fr) Inhibition de l'usp19
EP3773746A4 (fr) Variants d'aav6